Sitemap
May 06, 2008 Articles
Filter by Available Specialty
- Biem Pharmaceuticals to commercialize InSite's AzaSite in Turkey
- Long-term study analysis finds diabetic Latinos at high risk of retinopathy, macular edema
- Neoadjuvant lapatinib treatment decreased tumorigenic breast cancer stem cells
- One year of TZD treatment may increase fracture risk
- Oxigene posts $5.4 million net loss in first quarter
- Regeneron reports $11.6 million net loss, $56.4 million in total revenue for first quarter
- Surgery may be the best option for ACL rupture patients older than 40 years